Literature DB >> 16729034

Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle.

Luigi Anastasia1, Maurilio Sampaolesi, Nadia Papini, Diego Oleari, Giuseppe Lamorte, Cristina Tringali, Eugenio Monti, Daniela Galli, Guido Tettamanti, Giulio Cossu, Bruno Venerando.   

Abstract

Stem cells hold a great potential for the regeneration of damaged tissues in cardiovascular or musculoskeletal diseases. Unfortunately, problems such as limited availability, control of cell fate, and allograft rejection need to be addressed before therapeutic applications may become feasible. Generation of multipotent progenitors from adult differentiated cells could be a very attractive alternative to the limited in vitro self-renewal of several types of stem cells. In this direction, a recently synthesized unnatural purine, named reversine, has been proposed to induce reversion of adult cells to a multipotent state, which could be then converted into other cell types under appropriate stimuli. Our study suggests that reversine treatment transforms primary murine and human dermal fibroblasts into myogenic-competent cells both in vitro and in vivo. Moreover, this is the first study to demonstrate that plasticity changes arise in primary mouse and human cells following reversine exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16729034     DOI: 10.1038/sj.cdd.4401958

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  21 in total

1.  A chemical approach to myocardial protection and regeneration.

Authors:  Marco Piccoli; Federica Cirillo; Guido Tettamanti; Luigi Anastasia
Journal:  Eur Heart J Suppl       Date:  2016-04-29       Impact factor: 1.803

2.  Effect of reversine on cell cycle, apoptosis, and activation of hepatic stellate cells.

Authors:  Yu Huang; Di Huang; Jiefeng Weng; Shuai Zhang; Qiang Zhang; Zhenhao Mai; Weili Gu
Journal:  Mol Cell Biochem       Date:  2016-10-13       Impact factor: 3.396

3.  Specific differentiation of mesenchymal stem cells by small molecules.

Authors:  Heesang Song; Woochul Chang; Byeong-Wook Song; Ki-Chul Hwang
Journal:  Am J Stem Cells       Date:  2011-08-18

4.  Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells.

Authors:  Shih-Che Hua; Tien-Chun Chang; Hau-Ren Chen; Chieh-Hsiang Lu; Yi-Wen Liu; Shu-Hsin Chen; Hui-I Yu; Yi-Ping Chang; Ying-Ray Lee
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

5.  Effects of Different Concentrations of Reversine on Plasticity of Mesenchymal Stem Cells.

Authors:  Leila Soltani; Hamid Reza Rahmani; Morteza Daliri Joupari; Hori Ghaneialvar; Amir Hossein Mahdavi; Mehdi Shamsara
Journal:  Indian J Clin Biochem       Date:  2018-12-10

Review 6.  Mechanisms of urodele limb regeneration.

Authors:  David L Stocum
Journal:  Regeneration (Oxf)       Date:  2017-12-26

7.  The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells.

Authors:  Tze-Chen Hsieh; Frank Traganos; Zbigniew Darzynkiewicz; Joseph M Wu
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

8.  Reversine enhances generation of progenitor-like cells by dedifferentiation of annulus fibrosus cells.

Authors:  Mansi Saraiya; Rena Nasser; Yan Zeng; Sankar Addya; Ravi Kumar Ponnappan; Paolo Fortina; David Greg Anderson; Todd J Albert; Irving M Shapiro; Makarand V Risbud
Journal:  Tissue Eng Part A       Date:  2010-04       Impact factor: 3.845

9.  Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo.

Authors:  Hai-Xia Qin; Jun Yang; Hong-Kai Cui; Shao-Ping Li; Wei Zhang; Xiao-Li Ding; Yong-Hua Xia
Journal:  Cytotechnology       Date:  2013-03-10       Impact factor: 2.058

Review 10.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.